Content of review 1, reviewed on October 29, 2021

In this review, the authors address the antimycobacterial properties of delamanid (DLM, a new antituberculosis drug), report the global prevalence of DLM resistance, discuss the synergism of DLM with other anti-TB drugs, and evaluate the documented clinical trials to provide new insights into the clinical use of this antibiotic.

A comprehensive review on this promising antituberculosis antibiotic.

I have no conflicts of interest.

Source

    © 2021 the Reviewer (CC BY 4.0).

References

    Saeed, K., Elahe, T., Nourkhoda, S., Hassan, K. V., Hossein, H. M., Zahra, F., Ebrahim, K., Mehdi, G., Mohsen, H. 2021. Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis. Frontiers in Microbiology.